Neurology
We explore the depths of the brain to develop solutions for neurological conditions that impact millions of people worldwide. This constant driver of innovation enables us to charter new paths to life-transforming treatments.
A Decade of Innovation
Our commitment to neurology and the people living with these disorders has been unwavering. From helping to manage partial-onset (focal) seizures of epilepsy to supporting those living with Parkinson’s disease (PD), our ingenuity and innovative spirit are what helps us develop novel treatments that address the daily challenges people encounter living with serious neurological conditions.
Parkinson’s disease*
10M
1M
Epilepsy*
50M
3.4M
Our Medicines
KYNMOBI® (apomorphine HCl) sublingual film is a prescription medicine used to treat short-term (acute), intermittent “off” episodes in people with Parkinson’s disease (PD).
Please read the full Prescribing Information for KYNMOBI.
For HCP information, please visit: Visit KYNMOBI HCP site
For patient information, please visit: Visit KYNMOBI patient site
Aptiom® (eslicarbazepine acetate) is a prescription medicine to treat partial-onset seizures in patients 4 years of age and older.
Please read the full Prescribing Information for Aptiom.
For HCP information, please visit: Visit Aptiom HCP site
What is
Sunovion Answers?
We believe in putting people first, which is why we created Sunovion Answers. Our caring and skilled team is available to provide knowledge and resources to help patients, caregivers, family members, or providers. We’re committed to finding solutions and connecting people to the information they need.
Specialists are available anytime between 8AM and 8PM (ET): 1-855-552-8832
Our Neurology Pipeline
We strive to develop new treatments to help people living with neurologic disorders manage their symptoms. From supporting patients living with neuropathic pain to more advancements in Parkinson’s disease, we are leading the way to a healthier world.
Therapeutic Area
Candidate
Indication/Target
Phase
Neurology
Ulotaront (SEP-363856)
Parkinson’s disease psychosis
Phase 2 50% complete
Neurology
DSP-3905
Neuropathic pain
Phase 1 25% complete
Neurology
SEP-380135
Agitation in Alzheimer’s disease
Phase 1 25% complete
Therapeutic Area
Indication/Target
Candidate
Neurology
Parkinson’s disease psychosis
Ulotaront
(SEP-363856)
Phase 2 50% complete
Neurology
Neuropathic pain
DSP-3905
Phase 1 25% complete
Neurology
Agitation in Alzheimer’s disease
SEP-380135
Phase 1 25% complete
Featured Publications
Each day I am driven to live Sunovion’s value to serve and create value for patients, and work with our team to focus on developing novel treatments for CNS conditions.
